Back to Search
Start Over
Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol.
- Source :
-
European journal of medicinal chemistry [Eur J Med Chem] 2019 Feb 01; Vol. 163, pp. 1-9. Date of Electronic Publication: 2018 Nov 22. - Publication Year :
- 2019
-
Abstract
- VEGFR-2, Tie-2, and EphB4 are essential for both angiogenesis and tumorigenesis. Herein, we developed a series of pyridines incorporated with 1,2,3-triazole as multi-target inhibitors based on the crystal structure alignment of the kinase domain of angiogenic RTKs. Biological results indicated that these multi-target inhibitors displayed considerable potential as novel anti-angiogenic agents. Among them, compound BD7 exhibited the most potent inhibition against the three RTKs simultaneously, and good activity on inhibiting viability of human umbilical endothelial cells. Therefore, 1,2,3-triazole could serve as a promising DFG binding group for multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 bearing pyridine as hinge binding group.<br /> (Copyright © 2018 Elsevier Masson SAS. All rights reserved.)
- Subjects :
- Angiogenesis Inhibitors pharmacology
Cell Survival drug effects
Drug Discovery
Human Umbilical Vein Endothelial Cells
Humans
Protein Kinases
Angiogenesis Inhibitors chemical synthesis
Pyridines chemistry
Receptor, EphB4 antagonists & inhibitors
Receptor, TIE-2 antagonists & inhibitors
Triazoles chemistry
Vascular Endothelial Growth Factor Receptor-2 antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1768-3254
- Volume :
- 163
- Database :
- MEDLINE
- Journal :
- European journal of medicinal chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 30503935
- Full Text :
- https://doi.org/10.1016/j.ejmech.2018.11.042